8-K: Lifeward Achieves Record Revenue in 2023, Completes Integration and Eyes Growth

Lifeward, formerly ReWalk Robotics, reported record annual revenue of $13.9 million for 2023 and completed its operational integration, expecting $3 million in annual savings.

Summary

• Lifeward, previously known as ReWalk Robotics, announced its financial results for the fourth quarter and full year ended December 31, 2023.
• The company achieved record annual revenue of $13.9 million in 2023, a 151% increase compared to $5.5 million in 2022.
• Fourth-quarter revenue reached $6.9 million, a 216% increase from $2.2 million in the same period of 2022.
• The integration of ReWalk and AlterG businesses is complete, with expected annual net savings of $3 million in 2024.
• The company's new corporate branding as Lifeward was officially launched.
• The Centers for Medicare & Medicaid Services (CMS) finalized the 2024 Home Health Rule, including exoskeletons in the Medicare brace benefit category, effective January 1, 2024.
• Lifeward expects 2024 revenue to be between $28 and $32 million, with non-GAAP gross margin expanding to the high 40%s.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record revenue, successful integration, and positive future guidance. However, the operating losses and cash burn temper the overall optimism.

Positives

• The company achieved record annual revenue, demonstrating strong growth.
• The successful integration of ReWalk and AlterG is expected to yield significant cost savings.
• The new Medicare reimbursement for exoskeletons is a major positive development for the company.
• Lifeward has a strong cash position with $28.1 million in unrestricted cash and no debt.
• The company anticipates significant revenue growth in 2024.

Negatives

• The company experienced an operating loss of $6.1 million in the fourth quarter of 2023.
• The non-GAAP gross margin declined by 5.8 percentage points in Q4 2023 compared to Q4 2022.
• Cash used in operations was $4.4 million during the fourth quarter of 2023.
• The company's net loss was $5.6 million, or $(0.13) per share, for the fourth quarter of 2023.

Risks

• The company's ability to realize the anticipated benefits of the AlterG acquisition is subject to risk.
• There are uncertainties associated with future clinical trials and the regulatory approval process.
• The company's ability to achieve reimbursement from third-party payors, including CMS, is not guaranteed.
• The company has a limited operating history and needs to leverage its sales and marketing infrastructure.
• The company's ability to maintain compliance with Nasdaq listing requirements is a risk.

Future Outlook

Lifeward expects 2024 to be a year of achievement as it transitions into a growth phase, with revenue between $28 and $32 million, non-GAAP gross margin expanding to the high 40%s, and non-GAAP operating loss declining to the low double-digit millions. The company anticipates revenue growth in subsequent quarters of 2024 due to the phasing in of Medicare revenue and the contribution of the AlterG new product introduction expected to start mid-year.

Management Comments

• Larry Jasinski, Chief Executive Officer of Lifeward, stated that the organizational integration work is now completed, and the company is in an ideal position to move forward with its strategy.
• Jasinski also mentioned that the team is well prepared to support existing and new customers and maximize the opportunity created by the new Medicare benefit category for exoskeletons.

Industry Context

This announcement comes as the medical device industry is increasingly focused on innovative rehabilitation solutions. The inclusion of exoskeletons in the Medicare brace benefit category is a significant development that could drive adoption of these technologies. Lifeward's integration of ReWalk and AlterG positions it to capitalize on this trend, offering a broader range of rehabilitation solutions.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 151% revenue growth year-over-year is significantly higher than the average growth rate for medical device companies, which typically ranges from 5% to 15%.
• The integration of two companies and the resulting $3 million in annual savings is a positive sign of operational efficiency, which is a key metric for investors.
• The expansion of gross margin to the high 40%s is a positive sign, but it is important to compare this to other medical device companies with similar product offerings to determine if it is competitive.
• The company's focus on non-GAAP metrics is common in the industry, but investors should also consider the GAAP results to get a full picture of the company's financial health.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and cost savings.
• Employees will be part of a unified team with a broader mission.
• Customers will have access to a wider range of innovative rehabilitation solutions.
• Suppliers and distributors will have the opportunity to grow with the company.

Next Steps

• Lifeward will focus on executing its growth strategy in 2024.
• The company will work to maximize the opportunity created by the new Medicare benefit category for exoskeletons.
• Lifeward will continue to integrate the AlterG business and introduce new products.
• The company will announce the final Medicare reimbursement pricing during the first quarter of 2024.

Key Dates

Keywords

Lifeward, ReWalk Robotics, exoskeleton, Medicare, rehabilitation, AlterG, revenue, financial results, integration, gross margin